OS Therapies (NYSEAMERICAN:OSTX) Posts Earnings Results

Posted by on Aug 15th, 2026

OS Therapies (NYSEAMERICAN:OSTX – Get Free Report) released its earnings results on Friday. The company reported ($0.20) earnings per share (EPS) for the quarter, FiscalAI reports.

OS Therapies Trading Up 1.3%

Shares of OS Therapies stock traded up $0.02 during trading hours on Friday, reaching $1.62. The stock had a trading volume of 401,244 shares, compared to its average volume of 282,064. The stock’s 50 day moving average is $1.68 and its 200 day moving average is $1.57. OS Therapies has a twelve month low of $1.15 and a twelve month high of $2.57. The firm has a market capitalization of $73.77 million, a PE ratio of -1.50 and a beta of -0.73.

Hedge Funds Weigh In On OS Therapies

Large investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in shares of OS Therapies during the 4th quarter valued at approximately $39,000. Virtu Financial LLC lifted its holdings in OS Therapies by 252.0% during the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after purchasing an additional 54,269 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of OS Therapies in the third quarter valued at about $183,000. Geode Capital Management LLC grew its position in shares of OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after purchasing an additional 58,350 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in OS Therapies during the 3rd quarter worth approximately $169,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Zacks Research raised OS Therapies from a “strong sell” rating to a “hold” rating in a report on Thursday, June 4th. D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a report on Thursday, April 30th. Roth Capital assumed coverage on shares of OS Therapies in a report on Thursday, July 9th. They set a “buy” rating and a $7.00 target price for the company. Finally, Lake Street Capital decreased their target price on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.33.

Read Our Latest Research Report on OS Therapies

About OS Therapies

(Get Free Report)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Featured Stories

Earnings History for OS Therapies (NYSEAMERICAN:OSTX)

Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.